PHK
SUPN icon

Point72 Hong Kong’s Supernus Pharmaceuticals SUPN Stock Holding History

Point72 Hong Kong’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-115
Closed -$4K – 1493
2022
Q3 		$4K Buy
+115
New +$3.74K ﹤0.01% 1815
2022
Q1 		– Sell
-135
Closed -$4K – 2295
2021
Q4 		$4K Buy
+135
New +$4.1K ﹤0.01% 1747
2020
Q3 		– Sell
-1,215
Closed -$29K – 1517
2020
Q2 		$29K Buy
+1,215
New +$26.8K ﹤0.01% 835
2020
Q1 		– Sell
-166
Closed -$4K – 1341
2019
Q4 		$4K Buy
+166
New +$4.03K ﹤0.01% 1056
2019
Q3 		– Sell
-1,692
Closed -$56K – 1326
2019
Q2 		$56K Buy
1,692
+1,293
+324% +$44.3K 0.02% 619
2019
Q1 		$14K Buy
399
+369
+1,230% +$13.7K 0.01% 724
2018
Q4 		$1K Buy
+30
New +$1.29K ﹤0.01% 817
2018
Q3 		– Sell
-32
Closed -$2K – 1164
2018
Q2 		$2K Buy
+32
New +$1.66K ﹤0.01% 792
2018
Q1 		– Sell
-284
Closed -$11K – 1145
2017
Q4 		$11K Buy
+284
New +$11.2K 0.01% 481
2017
Q1 		– Sell
-389
Closed -$10K – 966
2016
Q4 		$10K Buy
+389
New +$8.69K 0.01% 655

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Point72 Hong Kong's SUPN Position: Q4 2022 in Review

Point72 Hong Kong sold out of Supernus Pharmaceuticals (SUPN) in Q4 2022, closing a stake of 115 shares — an estimated $4K sold.

Point72 Hong Kong first reported a position in SUPN in Q4 2016 and held it in 10 quarters. The position peaked at $56K in Q2 2019. 263 funds tracked by Wall St. Rank hold SUPN as of Q4 2022.

  • Point72 Hong Kong reported no remaining Supernus Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 115 Supernus Pharmaceuticals shares in Q4 2022, an estimated $4K.
  • Point72 Hong Kong first reported a position in Supernus Pharmaceuticals in Q4 2016 and held it in 10 quarters.
  • Point72 Hong Kong's Supernus Pharmaceuticals position peaked at $56K in Q2 2019.
  • 263 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2022.

Based on Point72 Hong Kong's 13F filing for Q4 2022, filed 14 Feb 2023.